

Author Correction: Secukinumab Demonstrates Significantly Lower Immunogenicity Potential Compared to Ixekizumab

Sebastian Spindeldreher · Bernard Maillère · Evelyne Correia ·
Maxime Tenon · Anette Karle · Philip Jarvis · Frank Kolbinger

Published online: March 17, 2018
© The Author(s) 2018

Author Correction to: Dermatol Ther (Heidelb)
(2018) 8:57–68
[https://doi.org/10.1007/
s13555-018-0220-y](https://doi.org/10.1007/s13555-018-0220-y)

In the original publication, information regarding “ustekinumab” was incorrectly published under the Methods section. The correct information in the section “Antibodies and Control Protein” should be “(secukinumab, 150 mg/mL; ixekizumab, 90 mg/mL; adalimumab, 50 mg/mL; ustekinumab 90 mg/ml)”. Infliximab, which is mentioned in that section, was not used in the study.

Open Access. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits any non-commercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

The original article can be found online at <https://doi.org/10.1007/s13555-018-0220-y>.

S. Spindeldreher (✉) · P. Jarvis · F. Kolbinger
Novartis Institutes for BioMedical Research,
Novartis Pharma AG, Basel, Switzerland
e-mail: Sebastian.Spindeldreher@novartis.com

B. Maillère · E. Correia · M. Tenon
CEA-Saclay, Institut Frédéric Joliot, SIMOPRO,
Université Paris-Saclay, 91191 Gif-Sur-Yvette, France

A. Karle
Integrated Biologics Profiling Unit, Immunogenicity
Risk Assessment, Novartis Pharma AG, Basel,
Switzerland